



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Docket No.: 2945-A

Barbara K. Finck et al.

Serial No.: 09/602,351

Art Unit: 1614

Filed: June 23, 2000

Examiner: Unassigned

For: SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TREATMENT OF MEDICAL DISORDERS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

BOX NON FEE

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56, §1.97, Applicants hereby disclose publications known to them which may be material to the patentability of this invention. The publications are listed on the attached Form PTO-1449, and a copy of each listed publication is included herewith. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

Submission of these publications does not constitute an admission that any are "prior art" under 35 U.S.C. §102 or §103, and Applicants specifically reserve the right to antedate any such material as by a showing under 37 C.F.R. §1.131 or other method. Applicants submit that the claims of the above-captioned application are directed to subject matter which is patentably distinct from the disclosures of the above-cited references.

Respectfully submitted,

*Diana K. Sheiness*

Diana K. Sheiness  
Registration No. 35,356

Immunex Corporation  
Law Department  
51 University Street  
Seattle, WA 98101  
Telephone (206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX NON-FEE, Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date: January 5, 2001

Signed: Camilla C. Edwards

Camilla C. Edwards

GP 1614  
HSDP  
RECEIVED  
JAN 16 2001  
RECEIVED  
JAN 31 2001  
TECH CENTER 16002300  
TECH CENTER 16002300